Skip to main content
SpringerLink
Log in

Activation of PPAR-γ inhibits differentiation of rat osteoblasts by reducing expression of connective tissue growth factor

  • Published:
Journal of Huazhong University of Science and Technology [Medical Sciences] Aims and scope Submit manuscript

Summary

Long-term treatment with an agonist of peroxisome proliferator-activated receptor (PPAR)-γ is associated with bone fractures in the clinical practice. However, the mechanisms underlying the fractures are not fully understood. This study was aimed to examine the effect of rosiglitazone (an agonist of PPAR-γ) of different doses on the proliferation, differentiation, and transforming growth factor beta 1 (TGF-β1)-induced expression of connective tissue growth factor (CTGF) in primary rat osteoblasts in vitro. Osteoblasts were isolated from newly born SD rats and treated with different doses of rosiglitazone (0–20 μmol/L). The proliferation and differentiation of osteoblasts were measured by MTT assay and NPP assay, respectively. The expression of CTGF was determined by RT-PCR and Western blotting. The results showed that most isolated osteoblasts displayed strong alkaline phosphatase (ALP) activity and treatment with different doses of rosiglitazone did not affect their proliferation, but significantly inhibited the differentiation of osteoblasts in a dose-dependent manner. Moreover, treatment with different doses of rosiglitazone significantly reduced the TGF-β1-induced CTGF mRNA transcription and protein expression in a dose-dependent manner in rat osteoblasts. It was concluded that the activation of PPAR-γ may inhibit the differentiation of osteoblasts by reducing the TGF-β1-induced CTGF expression in vitro.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Selvamurugan N, Kwok S, Alliston T, et al. Transforming growth factor-beta 1 regulation of collagenase-3 expression in osteoblastic cells by cross-talk between the Smad and MAPK signaling pathways and their components, Smad2 and Runx2. J Biol Chem, 2004,279(18):19327–19334

    Article  PubMed  CAS  Google Scholar 

  2. Krishnaswami A, Ravi-Kumar S, Lewis JM. Thiazolidinediones: A 2010 perspective. Perm J, 2010,14(3):64–72

    PubMed  PubMed Central  Google Scholar 

  3. Newman AB, Kupelian V, Visser M, et al. Sarcopenia: alternative definitions and associations with lower extremity function. J Am Geriatr Soc, 2003,51(11):1602–1609

    Article  PubMed  Google Scholar 

  4. Broulik PD, Sefc L, Haluzik M. Effect of PPAR-gamma agonist rosiglitazone on bone mineral density and serum adipokines in C57BL/6 male mice. Folia Biol, 2011,57(4):133–138

    CAS  Google Scholar 

  5. Kawai M, Sousa KM, MacDougald OA, et al. The many facets of PPARgamma: novel insights for the skeleton. Am J Physiol Endocrinol Metab, 2010,299(1):E3–E9

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  6. Han JY, Kim YJ, Kim L, et al. PPARgamma agonist and angiotensin II receptor antagonist ameliorate renal tubulointerstitial fibrosis. J Korean Med Sci, 2010,25(1):35–41

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  7. Wu M, Melichian DS, Chang E, et al. Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptorgamma. Am J Pathol, 2009,174(2):519–533

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  8. Chen JR, Lazarenko OP, Wu X, et al. Obesity reduces bone density associated with activation of PPARgamma and suppression of Wnt/beta-catenin in rapidly growing male rats. PLoS One, 2010,5(10):e13704

    Article  PubMed  PubMed Central  Google Scholar 

  9. Gonzalez CR, Matzkin ME, Frungieri MB, et al. Expression of the TGF-beta1 system in human testicular pathologies. Reprod Biol Endocrinol, 2010,8(1):148–159

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  10. Wei J, Ghosh AK, Sargent JL, et al. PPARgamma downregulation by TGFs in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PloS One, 2010,5(11):e13778

    Article  PubMed  PubMed Central  Google Scholar 

  11. Zhang GY, Cheng T, Zheng MH, et al. Activation of peroxisome proliferator-activated receptor-gamma inhibits transforming growth factor-beta1 induction of connective tissue growth factor and extracellular matrix in hypertrophic scar fibroblasts in vitro. J Lab Clin Med, 2009,301(1):515–522

    CAS  Google Scholar 

  12. Shi JQ, Xie M, Wang YJ, et al. The effect or rosiglitazone on signal pathways of transforming growth factor-beta1 in human lung fibroblast. Zhonghua Yan Ke Za Zhi (Chinese), 2008,44(5):413–417

    Google Scholar 

  13. Samarakoon R, Goppelt-Struebe M, Higgins PJ. Linking cell structure to gene regulation: signaling events and expression controls on the model genes PAI-1 and CTGF. Cell Signal, 2010,22(10):1413–1419

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  14. Sun K, Huang XH, Wang Q. Peroxisome proliferator-activated receptor gamma inhibits transforming growth factor beta1-induced connective tissue growth factor expression in rat hepatic stellate cells. J Bio Chem, 2009,29(49):45888–45894

    Google Scholar 

  15. Tan X, Dagher H, Hutton CA, et al. Effects of PPAR gamma ligands on TGF-beta1-induced epithelial-mesenhymal transition in alveolar epithelial cells. Respir Res, 2010,2(23):11–21

    Google Scholar 

  16. Gong K, Xing D, Li P, et al. Hypoxia induces downregulation of PPAR-gamma in isolated pulmonary arterial smooth muscle cells and in rat lung via transforming growth factor-beta signaling. AJP Lung Cel & Mol Physio, 2011,301(6):899–907

    Article  Google Scholar 

  17. Max T, Randy A, Tiffany B, et al. Ets-1 is essential for connective tissue growth factor (CTGF/CCN2) induction by TGF-β1 in osteoblasts. PLoS one, 2012, 4(4):e35258

    Google Scholar 

  18. Han P, Ji WP, Zhao CL, et al. Improved osteoblast proliferation, differentiation and mineralization on nanophase Ti6Al4V. Chin Med J, 2011,124(2):273–279

    PubMed  CAS  Google Scholar 

  19. Harslof T, Wamberg L, Moller L, et al. Rosiglitazone decreases bone mass and bone marrow fat. J Clin Endocrinol Metab, 2011,96(5):1541–1548

    Article  PubMed  Google Scholar 

  20. Bruedigam C, Eijken M, Koedam M, et al. A new concept underlying stem cell lineage skewing that explains the detrimental effects of thiazolidinediones on bone. Stem Cells, 2010,28(5):916–927

    PubMed  CAS  Google Scholar 

  21. Rzonca SO, Suva LJ, Gaddy D, et al. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology, 2004, 145(1):401–406

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  22. Akune T, Ohba S, Kamekura S, et al. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest, 2004,113(6):846–855

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  23. Chen R, Xue J, Xie ML. Reduction of isoprenaline-induced myocardial TGF-beta1 expression and fibrosis in osthole-treated mice. Toxicol Appl Pharmacol, 2011, 256(2):168–173

    Article  PubMed  CAS  Google Scholar 

  24. Arnott JA, Zhang X, Sanjay A, et al. Molecular requirements for induction of CTGF expression by TGF-beta1 in primary osteoblasts. Bone, 2008,42(5):871–885

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  25. Ohyama Y, Tanaka T, Shimizu T, et al. Runx2/Smad3 complex negatively regulates TGF-beta-induced connective tissue growth factor gene expression in vascular smooth muscle cells. J Atheroscler Thromb, 2012,19(1):23–35

    Article  PubMed  CAS  Google Scholar 

  26. Zhang X, Arnott JA, Rehman S, et al. Src is a major signaling component for CTGF induction by TGF-beta1 in osteoblasts. J Cell Physiol, 2010,224(3):691–701

    Article  PubMed  CAS  Google Scholar 

  27. Wang L, Zhang X, Guo Y, et al. Involvement of BMPs/Smad signaling pathway in mechanical response in osteoblasts. Cell Physiol Biochem, 2010,26(6):1093–1102

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China

    Wei-wei Yu  (余维巍), Qin Xia  (夏 秦), Yan Wu  (吴 艳) & Qiao-yun Bu  (卜巧云)

Authors
  1. Wei-wei Yu  (余维巍)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qin Xia  (夏 秦)
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yan Wu  (吴 艳)
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qiao-yun Bu  (卜巧云)
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Qin Xia  (夏 秦).

Additional information

This project was supported by the Natural Science Foundation of Hubei Province, China (No. 2010CDB09806).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yu, Ww., Xia, Q., Wu, Y. et al. Activation of PPAR-γ inhibits differentiation of rat osteoblasts by reducing expression of connective tissue growth factor. J. Huazhong Univ. Sci. Technol. [Med. Sci.] 34, 652–656 (2014). https://doi.org/10.1007/s11596-014-1332-y

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-014-1332-y

Key words

Search

Navigation